Why Semaglutide is an inflection point for India’s generics sector?
More than a supply chain issue and missing the first mover status, Semaglutide episode has rather exposed systemic chinks and could prove costly for India’s pharmaceutical industry, which supplies about 20% of the world’
By Project Chintan Newsroom
15 July 2026 · 1 min read
More than a supply chain issue and missing the first mover status, Semaglutide episode has rather exposed systemic chinks and could prove costly for India’s pharmaceutical industry, which supplies about 20% of the world’s generic medicines by volume.
Source: The Hindu — Sci-Tech